Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 446 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GLP 1 Clear all

Conditions: Type 1 Diabetes
Interventions: CT-868, Placebo, Victoza; Drug
Lead sponsor: Carmot Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: NNC0114-0006, liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: La Jolla, California • Northridge, California • Aurora, Colorado + 10 more

Conditions: Crohn Disease
Interventions: Tirzepatide, Mediterranean diet; Drug · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Monogenic Diabetes
Interventions: GLP-1, Exendin 9-39; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 89 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy, Growth Hormone Deficiency
Interventions: growth hormone and lirglutide, growth hormone, liraglutide, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder, Obesity
Interventions: LIRAGLUTIDE, Placebo; Drug · Other
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Type 2 Diabetes, Cardiac Disease
Interventions: Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 386,301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Overweight, Obesity
Interventions: LY3457263, Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: GLP-1 receptor agonist, Insulin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Overweight or Obesity
Interventions: Olatorepatide, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Mobile, Alabama • Walnut Creek, California • Waterbury, Connecticut + 17 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Epic-Based Clinician Notification, Usual Care; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Plano, Texas

Conditions: Long COVID
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Interventions: Semaglutide Pen Injector, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more

Conditions: Pre-diabetes, Type 2 Diabetes
Interventions: Exenatide, Sitagliptin, Glimepiride; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Laxity; Skin
Interventions: Sculptra Aesthetic; Device
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Type 2 Diabetes
Interventions: Cycloset; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 30 Years to 69 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/liraglutide, liraglutide, exenatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 85
States / cities: Birmingham, Alabama • Goodyear, Arizona • Mesa, Arizona + 73 more

Conditions: Obesity
Interventions: Liraglutide, Oral Semaglutide, Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteers (HV)
Interventions: Investigational Drug: IBI3042, Matching Placebo; Drug
Lead sponsor: Fortvita Biologics (USA)Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Type 2 Diabetes Mellitus
Interventions: 50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea; Drug · Other
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 93
States / cities: Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more

Conditions: Overweight and Obesity
Interventions: Apitegromab, Placebo, Tirzepatide; Drug
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more

Conditions: Obesity, Overweight
Interventions: Tirzepatide, Placebo, Liraglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baton Rouge, Louisiana • Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 1, Endothelial Dysfunction
Interventions: Dulaglutide, Placebo; Drug
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 40 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Orlando, Florida

Search by objective public record fields.

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Effects of GH and Lirglutide on AgRP

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

A Study of LY3457263 in Obese Participants

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

Impact of Liraglutide 3.0 on Body Fat Distribution

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

The Long COVID Treatment Trial

GLP-1R Agonist Treatment for Opioid Use Disorder

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

Assess Impact of Poly-L-lactic Acid on GLP1 Subjects

Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

A Study of IBI3042 in Healthy Adult Participants

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

A Study of Tirzepatide in Overweight and Very Overweight Participants

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes